A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of Various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older
Latest Information Update: 05 Feb 2025
At a glance
- Drugs JNJ 64400141 (Primary) ; JNJ 78991172 (Primary) ; JNJ 86051823 (Primary) ; JNJ-64213175 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Janssen Vaccines and Prevention B.V
Most Recent Events
- 22 Feb 2023 Status changed from recruiting to discontinued.
- 09 Feb 2023 This trial has been discontinued in Spain.
- 02 Aug 2022 Planned End Date changed from 17 Nov 2028 to 18 Jun 2029.